Drugs / Parstuzumab
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05918328 Comparator | May 2023 → Dec 2025 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parstuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05918328 ↗ |